Aptose Biosciences (TSE:APS) has released an update.
Aptose Biosciences has initiated a pilot clinical study of its new Tuspetinib (TUS) triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients, aiming to improve response rates and survival. The therapy, which combines TUS with venetoclax and a hypomethylating agent (VEN+HMA), has shown promising results in pre-clinical models and prior trials with relapsed/refractory AML. Aptose expects to share initial data from the study before the end of the year, with clinical sites currently being activated for the trial.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
